BNCM AND DELEX HEALTHCARE MERGER
Bounce Mobile Systems Inc. (BNCM) and DELEX Healthcare Group Inc. (DELEX) have successfully completed their merger and unveiled their post-merger and management plans.
POST MERGER PLANS
1. Management Transfer
The transition of BNCM management to DELEX will commence in January 2025. BNCM’s team will continue to provide advisory support to the new management on compliance and operational matters during this transition period, ensuring a smooth handover of responsibilities.
2. BNCM Q3 FS Report
BNCM’s Q3 Financial Statement (FS) will reflect DELEX’s revenue, assets, and liabilities, providing stakeholders with transparency regarding the merger’s financial impacts.
3. Asset & Revenue Transfer to BNCM
The transfer of DELEX’s assets and revenues to BNCM will be completed by November 15, 2024, alongside the transfer of shares representing 59.25% of the shareholding to DHG management.
4. Post Merger Share Structure
DELEX Group will hold a majority stake in BNCM, accounting for 59.25%, while BNCM will hold 15.75%, with other shareholders retaining the remaining shares. This post-merger share structure will be finalized and announced in the Q4 report.
5. Announcement of Name Change and Ticker Symbol
A formal application to rename BNCM to DELEX and update the ticker symbol will be applied by Q1 2025, aligning with the new direction of the merged company.
6. Regulation A Application
DELEX will apply for Regulation A with the SEC to support its expansion plans from March 2025.
7. DELEX Expansion Plans
DELEX is positioned for aggressive growth, with several key initiatives
STRENGTHS & EXPANSION PLANS
1. 15 Years of Business Growth
Strong Growth for the past 15 Years
DELEX Pharma, has operated for 15 Years and ranked as the 3rd largest national company in hospital channels according to IQVIA. DELEX Pharma’s Board and Executive Committee bring over more than 3 decades of experience or and leadership in the healthcare sector, reinforcing the company’s continuous growth.
2. Various FDA Licenses and Permits
DELEX Pharma holds various FDA licenses and permits
Delex Pharma currently holds various licenses and permits issued by the Philippines Food and Drug administration for (i) Importer/ Wholesaler/Distributor of Drugs (ii) Importer of Medical Devices (iii) Food Wholesaler, (iv) Cosmetic Importer and Wholesaler and (v) Drugstore Operator, including Online Order and Delivery.
3. Expand Distribution Channels
Supplies to nearly 700 Hospitals Nationwide
DELEX is expanding its distribution channels by forging strategic partnerships with healthcare providers to create integrated healthcare solutions. DELEX currently supplies to nearly 700 hospitals nationwide and has established a presence in over 900 Mercury Drug branches, serving more than 160 additional drug chains and reaching nearly 400 dispensing medical doctors and clinics, thereby leveraging market development. Looking ahead, DELEX aims to collaborate with more specialized care facilities to strengthen its value proposition and support the broader healthcare ecosystem in the Philippines.
4. Expand Product Development
DELEX currently holds over 30 Hospital Products approved by the Philippine FDA
DELEX currently holds over 30 Hospital Products approved by the Philippine FDA, more than 20 medical device products, and over 4 women’s health brands, all contributing to the company’s revenue growth. In the first quarter of the year, DELEX launched an impressive array of 11 new pharmaceutical products and secured distributorship agreements with 4 multinational medical device companies, positioning itself for significant growth across multiple therapeutic and diagnostic areas.
5. Expand Medical Device Business
Strategic Alliance with Amsino, Masimo, Verathon in the USA and StermMed (Germany)
To capitalize on the rapidly expanding medical device market in the Philippines, which is projected to grow at an annual rate of 8.14% (CAGR 2024-2029) and reach a market volume of US$1.39 billion by 2029, DELEX formed alliances with leading international medical device companies such as Amsino, Masimo, and Verathon in the U.S., as well as SternMed GmbH in Germany. These collaborations are anticipated to significantly enhance DELEX’s growth in the medical device business unit.
6. Expand Retail Pharmacy Business
Expand current 3 Pharmacy Stores to 60 in the coming years
A recent study highlights that the pharmacy market is projected to grow at an annual rate of 3.77% (CAGR 2024-2029), resulting in a market volume of approximately US$7.75 billion by 2029. In response to this opportunity, DELEX established its first branch in Barangay Sauyo, Quezon City in October 2021, to serve the densely populated community and surrounding areas during the pandemic. Since then, the company has expanded to two additional branches, totaling three drugstores, with two strategically located near hospitals to facilitate high-volume purchases. DELEX will continue to develop its drugstore business by positioning new locations near hospitals that accommodate prescription spills and by exploit untapped areas in the country to generate positive sales growth for the company.
7. Expand Market Reach Through DELEX ICU Forum
DELEX ICU Forum has reached almost 200,000 Healthcare Professionals Worldwide
DELEX has expanded its on-ground ICU Forum to online—a free webinar series for healthcare providers during the pandemic—that has since attracted a global audience of nearly 200,000 healthcare professionals. This platform facilitates discussions on best practices, advancements in critical care techniques, innovations in treatment protocols, and networking among healthcare communities. Additionally, this initiative has fostered partnerships with over 50 hospital departments and medical societies in the Philippines, significantly enhancing the company’s visibility among its target audience.
8. Expand Hospital Products
DELEX Acquires JMN Brothers Pharma
DELEX Pharma has acquired JMN Brothers Pharma Limited, Inc. (JMN Pharma) in 2022. JMN Pharma, established in 2018, is known for its expertise in women’s health and beauty, along with its ethical business in hospital products.
9. ISO-9001:2015 Certified
CPG Awards ISO-9001”2015 Re-Certification to DELEX
DELEX Pharma has once again demonstrated its unwavering commitment to quality and customer satisfaction by successfully passing the ISO 9001:2015 re-certification audit. The evaluation, conducted by Certification Partner Global (CPG), a leading international auditing firm, took place on July 12, 2024. The certification also marks a significant milestone in the company’s journey toward operational excellence.
10.Strong Distribution & Warehouse Capabilities
DELEX Distribution & Warehouse
DELEX has its own Trade Sales Team to strengthen an organized ordering system and distribution process. Distribution management is simplified effectively through the professional work of our highly trained team. Moreover, we have implemented the use of Systems Applications and Products-Enterprise Resource Planning (SAP ERP) for Order Processing & Inventory Control Management. Our Trade Sales Team has real-time information access to products in inventory. Hence, we can respond to the requests of customers on time.
11. Awards & Recognitions
DELEX Directors and Managers has received several awards and recognitions.
- Diversity Company of the Year for 2020 – awarded by Asia CEO Awards.
- Philippines Best Brand for 2019 – awarded by CMO Asia.
- SME Company of the Year – awarded by Asia CEO Awards.
- Executive Leadership Team of the Year for 2017 – awarded by Asia CEO Awards.
- Delex Pharma’s Chairman of the Board and CEO, J. de Ruyter Oroceo was awarded:
- Global Filipino Executive of the Year for 2020 – awarded by Asia CEO Awards
- Delex Pharma’s VP for Marketing, Lourdes Monasterio was awarded:
- Pioneering Woman Leader for 2020 – awarded by CMO Asia.
- Philippines Women Leader’s Award for 2019 – awarded by CMO Asia.
12. US$300 Billion Asia Pharmaceutical Market
Asia’s Growing Pharmaceutical Market
In 2024, the projected revenue for the Pharmaceuticals market in Asia is expected to reach a staggering US$238.10 billion. The largest market within this industry is Oncology Drugs, with a projected market volume of US$40.67billion in 2024. Looking ahead, the revenue is expected to display a steady annual growth rate (CAGR 2024-2029) of 5.06%, leading to a market volume of US$304.80billion by 2029.
DELEX Healthcare Group Inc.
Delex Healthcare Group Inc. (DELEX) was incorporated in 2017 in Delaware, USA. DELEX is engaged in the development and distribution of pharmaceutical and healthcare products through its subsidiaries, Delex Pharma International Inc. (Delex Pharma), DLX Holdings, Corp., and JMN Brother’s Pharma Limited, Inc.
DLX Holdings Inc., was incorporated in 2009. DLX holds a 60% stake in Delex Pharma International, Inc. in the Philippines. Delex Pharma is an ISO 9001:2015-certified pharmaceutical and medical device company, ranked as the 3rd largest among National Companies (NC) in hospital channels according to IQVIA. Delex Pharma’s Board Members and Directors have more than 15 years of experience in starting, expanding and managing a profitable and fast-growing Pharmaceutical company.
DELEX Pharma International Inc.
Delex Pharma International, Inc. (DPI) is a pharmaceutical and medical device company. It was established in 2009, inspired by its vision to provide patients with an alternative to quality and affordable products due to the rising cost of medication in the ICU setting. Delex Pharma currently has over 100 sales and marketing teams and over 1,000 distribution channels including hospitals, pharmacies, and healthcare centers across the country.
DELEX aims to close the gaps that patients experience in coping with the many difficulties in the ICU (Intensive Care Units) with alternative drugs that can meet those needs. In so doing, we stay true to our commitment of “meeting the gaps in critical care”.
PRESS RELEASE
1. BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth
2. BNCM and DELEX Healthcare Group, Inc. Announce their Expansion Plans to Solidify Market Presence
3. BNCM and DELEX Unveil Post-Merger Management Plans
4. BNCM Announces Strategic Partnership between Delex and Verathon
5. BNCM Announces 11 New Products from DELEX PHARMA to Propel Growth
6. BNCM Announces the Expansion of DELEX PHARMA’s Medical Device Business
7. BNCM Announces that DELEX ICU FORUMS has reached a Global Audience of almost 200,000 Healthcare Professionals
8. BNCM Announces DELEX Acquisition of JMN Brothers Pharma
9. BNCM: DELEX Critical Care Products Approved by the Philippine FDA
10 TIMELINE: BNCM COMPLETES MERGER WITH DELEX HEALTHCARE
11. BNCM: DELEX to Revolutionize ICU with its FDA Approved Products
12. BNCM: DELEX ANNOUNCE EXPANSION PLANS FOR ITS PHARMACY
13. BNCM Announces its Q3 and 9-Month Growth Results for 2024
14. BNCM: DELEX PHARMA Bolsters Market Reach Through 6 Major Conventions in November 2024
15. DELEX Announces its Partnership with Masimo to Revolutionize Critical Care in the Philippines
Disclaimer: Forward-Looking Statements
Certain information set forth by BNCM-DELEX group through presentation and publishing including those in websites and in other platforms may contain “forward-looking information,” including “future-oriented financial information,” and “financial outlook,” under applicable securities laws. These statements may contain information about financial prospects, projections, economic conditions, trends and uncertainties, and involve risks. We caution that actual results could differ materially from management experts, depending on the outcome of certain factors. Forward looking statements are provided to understand company’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. Any or all forward-looking statements may or may not turn to be wrong thereby making these statements of no guarantee into its future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties which may cause variations in actual performance in future periods and may differ materially from any projections of future performance or results expressed or implied by such forward-looking statements, thus speaks only as of the date they are made. The Company undertakes no obligation to update or revise forward-looking statements except as required by applicable securities laws.